» Articles » PMID: 34921619

Feasibility of Artificial Intelligence-supported Assessment of Bone Marrow Infiltration Using Dual-energy Computed Tomography in Patients with Evidence of Monoclonal Protein - a Retrospective Observational Study

Overview
Journal Eur Radiol
Specialty Radiology
Date 2021 Dec 18
PMID 34921619
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To demonstrate the feasibility of an automated, non-invasive approach to estimate bone marrow (BM) infiltration of multiple myeloma (MM) by dual-energy computed tomography (DECT) after virtual non-calcium (VNCa) post-processing.

Methods: Individuals with MM and monoclonal gammopathy of unknown significance (MGUS) with concurrent DECT and BM biopsy between May 2018 and July 2020 were included in this retrospective observational study. Two pathologists and three radiologists reported BM infiltration and presence of osteolytic bone lesions, respectively. Bone mineral density (BMD) was quantified CT-based by a CE-certified software. Automated spine segmentation was implemented by a pre-trained convolutional neural network. The non-fatty portion of BM was defined as voxels > 0 HU in VNCa. For statistical assessment, multivariate regression and receiver operating characteristic (ROC) were conducted.

Results: Thirty-five patients (mean age 65 ± 12 years; 18 female) were evaluated. The non-fatty portion of BM significantly predicted BM infiltration after adjusting for the covariable BMD (p = 0.007, r = 0.46). A non-fatty portion of BM > 0.93% could anticipate osteolytic lesions and the clinical diagnosis of MM with an area under the ROC curve of 0.70 [0.49-0.90] and 0.71 [0.54-0.89], respectively. Our approach identified MM-patients without osteolytic lesions on conventional CT with a sensitivity and specificity of 0.63 and 0.71, respectively.

Conclusions: Automated, AI-supported attenuation assessment of the spine in DECT VNCa is feasible to predict BM infiltration in MM. Further, the proposed method might allow for pre-selecting patients with higher pre-test probability of osteolytic bone lesions and support the clinical diagnosis of MM without pathognomonic lesions on conventional CT.

Key Points: • The retrospective study provides an automated approach for quantification of the non-fatty portion of bone marrow, based on AI-supported spine segmentation and virtual non-calcium dual-energy CT data. • An increasing non-fatty portion of bone marrow is associated with a higher infiltration determined by invasive biopsy after adjusting for bone mineral density as a control variable (p = 0.007, r = 0.46). • The non-fatty portion of bone marrow might support the clinical diagnosis of multiple myeloma when conventional CT images are negative (sensitivity 0.63, specificity 0.71).

Citing Articles

Dual-energy CT-derived virtual noncalcium imaging to assess bone marrow lesions in patients with knee osteoarthritis.

Chen W, Liu L, Zhao H, Li H, Luo J, Qu Y Sci Rep. 2025; 15(1):3331.

PMID: 39870692 PMC: 11772839. DOI: 10.1038/s41598-025-86697-2.


Diagnosis of newly developed multiple myeloma without bone disease detectable on conventional computed tomography (CT) scan by using dual-energy CT.

Jiang N, Xia Y, Luo M, Chen J, Qiu Z, Liu J J Bone Oncol. 2024; 48:100636.

PMID: 39391582 PMC: 11466646. DOI: 10.1016/j.jbo.2024.100636.


The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management.

More S, Corvatta L, Manieri V, Morsia E, Offidani M Cancers (Basel). 2024; 16(12).

PMID: 38927968 PMC: 11202048. DOI: 10.3390/cancers16122263.


Correlation between vertebral bone mineral density and multi-level virtual non-calcium imaging parameters from dual-layer spectral detector computed tomography.

Yang Y, Hou J, Niu Y, Zhang Y, Luo T, Lu Q Quant Imaging Med Surg. 2024; 14(6):3803-3815.

PMID: 38846313 PMC: 11151250. DOI: 10.21037/qims-23-1543.


Updates on the Applications of Spectral Computed Tomography for Musculoskeletal Imaging.

Eibschutz L, Matcuk G, Chiu M, Lu M, Gholamrezanezhad A Diagnostics (Basel). 2024; 14(7).

PMID: 38611645 PMC: 11011285. DOI: 10.3390/diagnostics14070732.


References
1.
Ho M, Patel A, Goh C, Moscvin M, Zhang L, Bianchi G . Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia. 2020; 34(12):3111-3125. DOI: 10.1038/s41375-020-01051-x. View

2.
Kazandjian D . Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2017; 43(6):676-681. PMC: 5283695. DOI: 10.1053/j.seminoncol.2016.11.004. View

3.
Landgren O, Kyle R, Rajkumar S . From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res. 2011; 17(6):1243-52. PMC: 5901666. DOI: 10.1158/1078-0432.CCR-10-1822. View

4.
Sidiqi M, Aljama M, Kumar S, Jevremovic D, Buadi F, Warsame R . The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer J. 2020; 10(5):52. PMC: 7203099. DOI: 10.1038/s41408-020-0319-0. View

5.
Hjortholm N, Jaddini E, Halaburda K, Snarski E . Strategies of pain reduction during the bone marrow biopsy. Ann Hematol. 2012; 92(2):145-9. PMC: 3542425. DOI: 10.1007/s00277-012-1641-9. View